1. Clinical Overview
Pramipexole is a non-ergot dopamine agonist that selectively stimulates dopamine D2, D3, and D4 receptors. The 0.26mg strength is equivalent to 0.375mg of pramipexole dihydrochloride monohydrate, a common formulation in India for the treatment of Parkinson's disease and Restless Legs Syndrome (RLS). It helps restore dopamine function in the basal ganglia, improving motor control and reducing RLS symptoms.
| Onset | Duration | Bioavailability |
|---|---|---|
| Approximately 2 hours for Parkinson's disease; 1-2 hours for RLS. | Approximately 8-12 hours. | >90% |
2. Mechanism of Action
Pramipexole exerts its therapeutic effect by directly stimulating postsynaptic dopamine D2-type receptors (specifically D2, D3, and D4 subfamilies) in the striatum and other brain regions. This action compensates for the depleted dopamine levels characteristic of Parkinson's disease. In RLS, its mechanism is believed to involve modulation of dopaminergic pathways in the spinal cord and central nervous system.
3. Indications & Uses
- Idiopathic Parkinson's Disease (as monotherapy or adjunct to levodopa)
- Moderate to Severe Primary Restless Legs Syndrome (RLS)
4. Dosage & Administration
Adult Dosage: Parkinson's: Start 0.26mg (0.375mg salt) TID. Titrate weekly by 0.26mg/dose to max 1.5mg TID. RLS: Start 0.26mg once daily, 2-3 hours before bedtime. May increase to 0.52mg after 4-7 days if needed.
Administration: Take with food to reduce nausea. For RLS, take once daily 2-3 hours before bedtime. Tablets should be swallowed whole with water. Do not crush or chew. Maintain consistent timing of doses.
5. Side Effects
Common side effects may include:
- Nausea
- Dizziness
- Somnolence (daytime sleepiness)
- Insomnia
- Constipation
- Peripheral edema
- Headache
- Fatigue
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Levodopa/Carbidopa | Increased risk of dyskinesias, hallucinations, orthostasis. Synergistic therapeutic effect. | Major |
| Antipsychotics (e.g., Haloperidol, Risperidone) | Antagonism of dopaminergic effect, reducing pramipexole efficacy. | Major |
| Metoclopramide, Domperidone | Domperidone (peripheral) is safer. Metoclopramide (central) may antagonize effect. | Moderate |
| Antihypertensives | Additive hypotensive effect. | Moderate |
| Cimetidine | Reduces renal clearance of pramipexole, increasing AUC by ~50%. Requires dose adjustment. | Moderate |
| Other CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Additive sedative effects, increased risk of somnolence. | Moderate |
7. Patient Counselling
- DO take exactly as prescribed, with food if nausea occurs.
- DO rise slowly from sitting/lying position to avoid dizziness.
- DO report any new or increased urges (gambling, shopping, sexual thoughts) to your doctor immediately.
- DONT stop taking the medicine suddenly. Always taper under doctor's supervision.
- DONT drive or operate heavy machinery until you know how the medicine affects you.
- DONT consume alcohol while on this medication.
8. Toxicology & Storage
Overdose: Nausea, vomiting, hypotension, agitation, hallucinations, involuntary movements (dyskinesia), severe somnolence, cardiac arrhythmias (rare).
Storage: Store below 30°C. Protect from light and moisture. Keep in the original blister pack or container. Keep out of reach of children.